Previous 10 | Next 10 |
Cocrystal Pharma ( NASDAQ: COCP ) stock has risen 5.4% premarket after it said the single ascending dose portion of the Phase 1 study with its orally administered antiviral candidate CC-42344 for the treatment of pandemic and seasonal influenza A had been com...
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that pharmacokinetic (PK) data from the singl...
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for explorat...
If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 2...
Cocrystal Reported 1Q22 With Pipeline Updates. Cocrystal reported a 1Q22 loss of $4.2 million or $(0.04) per share. The company reviewed its recent clinical progress, including its ongoing Phase 1 study of CC-42344 in influenza and plans to initiate two Phase 1 studies of CC-45205 in COVID-19....
Cocrystal Pharma press release (NASDAQ:COCP): Q1 GAAP EPS of -$0.04 in-line. “Among our goals this year is to complete the CC-42344 Phase 1 influenza study and to initiate two Phase 1 COVID-19 studies with CDI-45205 and a novel, broad-spectrum orally administered pr...
Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A Announced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the Companyȁ...
Cocrystal Pharma (COCP) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>
Cocrystal Pharma (NASDAQ:COCP) signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies evaluating the potential of its 3CL protease inhibitors to treat COVID-19. The company said it applied its proprietary drug discovery platfor...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...